Abzena grants Telix rights to PSMA antibodies

Abzena plc (LSE:ABZA) granted Telix Pharmaceuticals Ltd. (North Melbourne, Australia) exclusive, worldwide rights to develop and commercialize therapeutics and diagnostics based on preclinical prostate-specific membrane antigen (PSMA; FOLH1; GCPII) antibodies. The companies said Telix plans to use the assets, which were created using Abzena’s Composite Human Antibody technology, to develop products for imaging and treating metastatic prostate cancer...